Compounds and methods for kinase modulation, and indications therefor
US-2016168146-A1 · Jun 16, 2016 · US
Kinase modulation and indications therefor
US9550768B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9550768-B2 |
| Application number | US-201313793881-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 11, 2013 |
| Priority date | May 17, 2011 |
| Publication date | Jan 24, 2017 |
| Grant date | Jan 24, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compounds, compositions and methods useful for treatment of Flt3-mediated diseases or conditions are provided herewith. Also provided herewith are methods for modulating the receptor protein tyrosine like kinase 3(Flt3).
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating a subject suffering from acute myeloid leukemia (AML), said method comprising administering to the subject an effective amount of a compound having the formula: or a pharmaceutically acceptable salt, tautomer or isomer thereof, wherein the subject has an FMS-like tyrosine kinase (Flt3) gene with an internal tandem duplication (ITD) mutation. 2. The method of claim 1 , wherein the Flt3 gene further comprises an amino acid substitution at residues F691, D835, Y842 or combinations thereof. 3. The method of claim 2 , wherein the amino acid substitution is selected from F691L, D835V/Y, Y842C/H and combinations thereof. 4. The method of claim 3 , wherein the amino acid substitution comprises F691L. 5. The method of claim 1 , wherein the administration is oral. 6. The method of claim 1 , wherein the effective amount is 0.1 mg/kg to 20 mg/kg.
Assignees
Inventors
Classifications
- C07D471/04Primary
Ortho-condensed systems · CPC title
- A61K31/4745Primary
condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48) · CPC title
Preparations for use in therapy · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9550768B2 cover?
- Compounds, compositions and methods useful for treatment of Flt3-mediated diseases or conditions are provided herewith. Also provided herewith are methods for modulating the receptor protein tyrosine like kinase 3(Flt3).
- Who is the assignee on this patent?
- Plexxikon Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D471/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).